TY - JOUR
T1 - Prediction of Mycobacterium tuberculosis pyrazinamidase function based on structural stability, physicochemical and geometrical descriptors
AU - Supo-Escalante, Rydberg Roman
AU - Médico, Aldhair
AU - Gushiken, Eduardo
AU - Olivos-Ramírez, Gustavo E.
AU - Quispe, Yaneth
AU - Torres, Fiorella
AU - Zamudio, Melissa
AU - Antiparra, Ricardo
AU - Mario Amzel, L.
AU - Gilman, Robert H.
AU - Sheen, Patricia
AU - Zimic, Mirko
N1 - Funding Information:
This research was funded by the Wellcome Trust Intermediate Fellowship (grant 099805/Z/12/Z) (PS). This study was also partially funded Grand Challenge Canada (grant 0687-01-10) (PS), by FONDECyT-Peru (grant 037-2014) (MZ). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Funding Information:
Funding:Thisresearchwasfundedbythe WellcomeTrustIntermediateFellowship(grant 099805/Z/12/Z)(PS).Thisstudywasalsopartially fundedGrandChallengeCanada(grant0687-01-10)(PS),byFONDECyT-Peru(grant037-2014) (MZ).Thefundershadnoroleinstudydesign,data
Publisher Copyright:
Copyright: © 2020 Supo-Escalante et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
PY - 2020/7
Y1 - 2020/7
N2 - Background: Pyrazinamide is an important drug against the latent stage of tuberculosis and is used in both first- and second-line treatment regimens. Pyrazinamide-susceptibility test usually takes a week to have a diagnosis to guide initial therapy, implying a delay in receiving appropriate therapy. The continued increase in multi-drug resistant tuberculosis and the prevalence of pyrazinamide resistance in several countries makes the development of assays for prompt identification of resistance necessary. The main cause of pyrazinamide resistance is the impairment of pyrazinamidase function attributed to mutations in the promoter and/or pncA coding gene. However, not all pncA mutations necessarily affect the pyrazinamidase function. Objective: To develop a methodology to predict pyrazinamidase function from detected mutations in the pncA gene. Methods: We measured the catalytic constant (kcat), KM, enzymatic efficiency, and enzymatic activity of 35 recombinant mutated pyrazinamidase and the wild type (Protein Data Bank ID = 3pl1). From all the 3D modeled structures, we extracted several predictors based on three categories: structural stability (estimated by normal mode analysis and molecular dynamics), physicochemical, and geometrical characteristics. We used a stepwise Akaike's information criterion forward multiple log-linear regression to model each kinetic parameter with each category of predictors. We also developed weighted models combining the three categories of predictive models for each kinetic parameter. We tested the robustness of the predictive ability of each model by 6-fold cross-validation against random models. Results: The stability, physicochemical, and geometrical descriptors explained most of the variability (R2) of the kinetic parameters. Our models are best suited to predict kcat, efficiency, and activity based on the root-mean-square error of prediction of the 6-fold cross-validation. Conclusions: This study shows a quick approach to predict the pyrazinamidase function only from the pncA sequence when point mutations are present. This can be an important tool to detect pyrazinamide resistance.
AB - Background: Pyrazinamide is an important drug against the latent stage of tuberculosis and is used in both first- and second-line treatment regimens. Pyrazinamide-susceptibility test usually takes a week to have a diagnosis to guide initial therapy, implying a delay in receiving appropriate therapy. The continued increase in multi-drug resistant tuberculosis and the prevalence of pyrazinamide resistance in several countries makes the development of assays for prompt identification of resistance necessary. The main cause of pyrazinamide resistance is the impairment of pyrazinamidase function attributed to mutations in the promoter and/or pncA coding gene. However, not all pncA mutations necessarily affect the pyrazinamidase function. Objective: To develop a methodology to predict pyrazinamidase function from detected mutations in the pncA gene. Methods: We measured the catalytic constant (kcat), KM, enzymatic efficiency, and enzymatic activity of 35 recombinant mutated pyrazinamidase and the wild type (Protein Data Bank ID = 3pl1). From all the 3D modeled structures, we extracted several predictors based on three categories: structural stability (estimated by normal mode analysis and molecular dynamics), physicochemical, and geometrical characteristics. We used a stepwise Akaike's information criterion forward multiple log-linear regression to model each kinetic parameter with each category of predictors. We also developed weighted models combining the three categories of predictive models for each kinetic parameter. We tested the robustness of the predictive ability of each model by 6-fold cross-validation against random models. Results: The stability, physicochemical, and geometrical descriptors explained most of the variability (R2) of the kinetic parameters. Our models are best suited to predict kcat, efficiency, and activity based on the root-mean-square error of prediction of the 6-fold cross-validation. Conclusions: This study shows a quick approach to predict the pyrazinamidase function only from the pncA sequence when point mutations are present. This can be an important tool to detect pyrazinamide resistance.
UR - http://www.scopus.com/inward/record.url?scp=85089126971&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85089126971&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0235643
DO - 10.1371/journal.pone.0235643
M3 - Article
C2 - 32735615
AN - SCOPUS:85089126971
SN - 1932-6203
VL - 15
JO - PLoS One
JF - PLoS One
IS - 7 July
M1 - e0235643
ER -